| # | Drug | Count |
|---|---|---|
| 0 | PREDNISONE | 40 |
| 1 | PREDNISOLONE | 35 |
| 2 | PREDNISOLONE ORAL | 35 |
| 3 | PREDNISOLONE ORAL SOLUTION | 35 |
| 4 | METHOTREXATE SODIUM | 34 |
| 5 | METHOTREXATE | 32 |
| 6 | PYRIDOSTIGMINE BROMIDE | 30 |
| 7 | AZATHIOPRINE | 27 |
| 8 | RITUXIMAB | 26 |
| 9 | ADALIMUMAB | 25 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | ESTRONE | 1 | 0.0093 |
| 1 | EFGARTIGIMOD ALFA | 18 | 0.0045 |
| 2 | PYRIDOSTIGMINE BROMIDE | 30 | 0.0039 |
| 3 | CARTEOLOL HYDROCHLORIDE | 1 | 0.0030 |
| 4 | EFGARTIGIMOD ALFA AND HYALURONIDASE (HUMAN RECOMBINANT) | 1 | 0.0021 |
| 5 | BEMPEDOIC ACID AND EZETIMIBE | 1 | 0.0014 |
| 6 | CHROMIC CHLORIDE | 1 | 0.0012 |
| 7 | PYRIDOSTIGMINE BROMIDE ORAL | 4 | 0.0011 |
| 8 | CHLORPROMAZINE HYDROCHLORIDE | 1 | 0.0010 |
| 9 | LUSPATERCEPT | 2 | 0.0008 |
| # | Drug class | Count |
|---|---|---|
| 0 | Corticosteroid [EPC] | 90 |
| 1 | Tumor Necrosis Factor Blocker [EPC] | 35 |
| 2 | Folate Analog Metabolic Inhibitor [EPC] | 32 |
| 3 | Purine Antimetabolite [EPC] | 27 |
| 4 | CD20-directed Cytolytic Antibody [EPC] | 26 |
| 5 | Complement Inhibitor [EPC] | 22 |
| 6 | Nonsteroidal Anti-inflammatory Drug [EPC] | 22 |
| 7 | Neonatal Fc Receptor Blocker [EPC] | 20 |
| 8 | Antirheumatic Agent [EPC] | 17 |
| 9 | Expectorant [EPC] | 16 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Neonatal Fc Receptor Blocker [EPC] | 20 | 0.0046 |
| 1 | Erythroid Maturation Agent [EPC] | 2 | 0.0008 |
| 2 | Adenosine Triphosphate-Citrate Lyase Inhibitor [EPC] | 2 | 0.0006 |
| 3 | Endoglycosidase [EPC] | 1 | 0.0005 |
| 4 | Anthracycline Topoisomerase Inhibitor [EPC] | 1 | 0.0004 |
| 5 | Complement Inhibitor [EPC] | 22 | 0.0004 |
| 6 | Human Immunoglobulin G [EPC] | 7 | 0.0003 |
| 7 | Bile Acid Sequestrant [EPC] | 4 | 0.0003 |
| 8 | Calcitonin [EPC] | 1 | 0.0003 |
| 9 | Purine Antimetabolite [EPC] | 27 | 0.0003 |